2061. Machine Learning Detects Symptomatic Plaques in Patients With Carotid Atherosclerosis on CT Angiography.
作者: Francesco Pisu.;Brady J Williamson.;Valentina Nardi.;Kosmas I Paraskevas.;Josep Puig.;Achala Vagal.;Gianluca de Rubeis.;Michele Porcu.;Riccardo Cau.;John C Benson.;Antonella Balestrieri.;Giuseppe Lanzino.;Jasjit S Suri.;Abdelkader Mahammedi.;Luca Saba.
来源: Circ Cardiovasc Imaging. 2024年17卷6期e016274页
This study aimed to develop and validate a computed tomography angiography based machine learning model that uses plaque composition data and degree of carotid stenosis to detect symptomatic carotid plaques in patients with carotid atherosclerosis.
2062. Myocardial Blood Flow by Magnetic Resonance in Patients With Suspected Coronary Stenosis: Comparison to PET and Invasive Physiology.
作者: Laust Dupont Rasmussen.;Theodore Murphy.;Xenios Milidonis.;Ashkan Eftekhari.;Salma Raghad Karim.;Jelmer Westra.;Jonathan Nørtoft Dahl.;Christin Isaksen.;Lau Brix.;June Anita Ejlersen.;Mette Nyegaard.;Jane Kirk Johansen.;Hanne Maare Søndergaard.;Jesper Mortensen.;Lars Christian Gormsen.;Evald Høj Christiansen.;Amedeo Chiribiri.;Steffen E Petersen.;Morten Bøttcher.;Simon Winther.
来源: Circ Cardiovasc Imaging. 2024年17卷6期e016635页
Despite recent guideline recommendations, quantitative perfusion (QP) estimates of myocardial blood flow from cardiac magnetic resonance (CMR) have only been sparsely validated. Furthermore, the additional diagnostic value of utilizing QP in addition to the traditional visual expert interpretation of stress-perfusion CMR remains unknown. The aim was to investigate the correlation between myocardial blood flow measurements estimated by CMR, positron emission tomography, and invasive coronary thermodilution. The second aim is to investigate the diagnostic performance of CMR-QP to identify obstructive coronary artery disease (CAD).
2066. Text Messages to Promote Physical Activity in Patients With Cardiovascular Disease: A Micro-Randomized Trial of a Just-In-Time Adaptive Intervention.
作者: Jessica R Golbus.;Jieru Shi.;Kashvi Gupta.;Rachel Stevens.;V Swetha E Jeganathan.;Evan Luff.;Thomas Boyden.;Bhramar Mukherjee.;Sarah Kohnstamm.;Vlad Taralunga.;Vik Kheterpal.;Sachin Kheterpal.;Kenneth Resnicow.;Susan Murphy.;Walter Dempsey.;Predrag Klasnja.;Brahmajee K Nallamothu.
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷7期e010731页
Text messages may enhance physical activity levels in patients with cardiovascular disease, including those enrolled in cardiac rehabilitation. However, the independent and long-term effects of text messages remain uncertain.
2068. Health-Status Outcomes in Older Patients With Myocardial Infarction: Physiology-Guided Complete Revascularization Versus Culprit-Only Strategy.
作者: Gianluca Campo.;Vincenzo Guiducci.;Javier Escaned.;Raul Moreno.;Gianni Casella.;Caterina Cavazza.;Enrico Cerrato.;Marco Contarini.;Marco Arena.;Andres Iniguez Romo.;Enrique Gutiérrez Ibañes.;Roberto Scarsini.;Giuseppe Vadalà.;Giuseppe Andò.;Gerlando Pilato.;Sergio Musto d'Amore.;Alessandro Capecchi.;Ramiro Trillo Nouche.;Elisabetta Moscarella.;Alfonso Gambino.;Marco Pavani.;Anna Zanetti.;Nicola Pesenti.;Dariusz Dudek.;Emanuele Barbato.;Matteo Tebaldi.;Simone Biscaglia.
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷7期e010490页
The FIRE trial (Functional Assessment in Elderly Myocardial Infarction Patients With Multivessel Disease) enrolled 1445 older (aged ≥75 years) patients with myocardial infarction and multivessel disease in Italy, Spain, and Poland. Patients were randomized to physiology-guided complete revascularization or treatment of the only culprit lesion. Physiology-guided complete revascularization significantly reduced ischemic adverse events at 1 year. This prespecified analysis investigated the changes between the 2 study groups in angina status, quality of life, physical performance, and frailty.
2069. American Heart Association Cardiogenic Shock Registry: Design and Implementation.
作者: David A Morrow.;Mariell Jessup.;William T Abraham.;Michael Acker.;Angeline Aringo.;Wayne Batchelor.;Joanna Chikwe.;Shaina Costello.;Stavros G Drakos.;Steven Farmer.;Annetine Gelijns.;Nicole Gillette.;Judith S Hochman.;Maria Isler.;Navin K Kapur.;Arman Kilic.;Robert Kormos.;Eldrin F Lewis.;JoAnn Lindenfeld.;Pierluca Lombardi.;Donna Mancini.;Sunil V Rao.;Christine Rutan.;Marc Samsky.;Mitchell W Krucoff.
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷7期e010637页
Cardiogenic shock is a morbid complication of heart disease that claims the lives of more than 1 in 3 patients presenting with this syndrome. Supporting a unique collaboration across clinical specialties, federal regulators, payors, and industry, the American Heart Association volunteers and staff have launched a quality improvement registry to better understand the clinical manifestations of shock phenotypes, and to benchmark the management patterns, and outcomes of patients presenting with cardiogenic shock to hospitals across the United States.
2070. Natural History of Coronary Atherosclerosis in Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement: The Role of Quantitative Flow Ratio.
作者: Iginio Colaiori.;Luca Paolucci.;Fabio Mangiacapra.;Emanuele Barbato.;Gian Paolo Ussia.;Francesco Grigioni.;Pierluigi Demola.;Marco Vitolo.;Giorgio Benatti.;Luigi Vignali.;Davide Gabbieri.;Paolo Magnavacchi.;Fabio Alfredo Sgura.;Giuseppe Boriani.;Vincenzo Guiducci.
来源: Circ Cardiovasc Interv. 2024年17卷8期e013705页
The prognostic impact of functionally significant coronary artery disease, as assessed with quantitative flow ratio (QFR), in patients with severe aortic stenosis treated with transcatheter aortic valve replacement is unknown.
2071. Ultrasound-Guided Transfemoral Access for Coronary Procedures: A Pooled Learning Curve Analysis From the FAUST and UNIVERSAL Trials.
作者: Marc-André d'Entremont.;Arnold H Seto.;Sulaiman Alrashidi.;Omar Alansari.;Bradley Brochu.;Samuel Lemaire-Paquette.;Laura Heenan.;Elizabeth Skuriat.;Jessica Tyrwhitt.;Michael Raco.;Michael B Tsang.;Nicholas Valettas.;James Velianou.;Tej Sheth.;Matthew Sibbald.;Shamir R Mehta.;Natalia Pinilla-Echeverri.;Jon-David Schwalm.;Madhu K Natarajan.;Mazen Abu-Fadel.;Andrew Kelly.;Elie Akl.;Sarah Tawadros.;Walaa Faidi.;John Bauer.;Rachel Moxham.;James Nkurunziza.;Gustavo Dutra.;Jose Winter.;Étienne L Couture.;Sanjit S Jolly.
来源: Circ Cardiovasc Interv. 2024年17卷8期e013817页
The learning curve for new operators performing ultrasound-guided transfemoral access (TFA) remains uncertain.
2072. Nonpharmacological Approaches to Managing Heart Failure With Preserved Ejection Fraction.
作者: Feiyang Tang.;Haofu Han.;Sheng Fu.;Qiming Liu.;Shenghua Zhou.;Jiapeng Huang.;Yichao Xiao.
来源: Circ Heart Fail. 2024年17卷8期e011269页
Heart failure with preserved ejection fraction (HFpEF) is a common subtype of heart failure marked by impaired left ventricular diastolic function and decreased myocardial compliance. Given the limited availability of evidence-based pharmacological treatments for HFpEF, there is a growing interest in nonpharmacological interventions as viable therapeutic alternatives. This review aims to explore the pathophysiology of HFpEF and present recent advancements in nonpharmacological management approaches, encompassing noninvasive therapies, invasive procedures and targeted treatments for comorbidities. An extensive literature review was undertaken to identify and synthesize emerging nonpharmacological treatment options for HFpEF, assessing their potential to enhance patient outcomes. Nonpharmacological strategies, such as vagus nerve stimulation, percutaneous pulmonary artery denervation, renal denervation, transcatheter insertion of atrial shunts and pericardial resection, demonstrate promising potential for alleviating HFpEF symptoms and improving patient prognosis. Moreover, addressing comorbidities, such as hypertension and diabetes, may offer additional therapeutic benefits. These cutting-edge techniques, in conjunction with well-established exercise therapies, pave the way for future research and clinical applications in the field. Nonpharmacological interventions hold promise for advancing HFpEF patient care and fostering a deeper understanding of these treatment approaches, which will facilitate new clinical applications and contribute to the development of more targeted therapies.
2073. Sex Differences in Outcomes of an Intensive Risk Factor Modification Program in Patients With Atrial Fibrillation.
作者: Jean Jacques Noubiap.;Rajeev K Pathak.;Gijo Thomas.;Adrian D Elliott.;Prashanthan Sanders.;Melissa E Middeldorp.
来源: Circ Arrhythm Electrophysiol. 2024年17卷7期e012534页
The outcomes of atrial fibrillation (AF) seem to be variable between males and females. We therefore aimed to determine sex differences in weight loss, cardiorespiratory fitness gain, and recurrence and progression of AF following risk factor management.
2075. Advanced Cardiac Patches for the Treatment of Myocardial Infarction.
作者: Tailuo Liu.;Ying Hao.;Zixuan Zhang.;Hao Zhou.;Shiqin Peng.;Dingyi Zhang.;Ka Li.;Yuwen Chen.;Mao Chen.
来源: Circulation. 2024年149卷25期2002-2020页
Myocardial infarction is a cardiovascular disease characterized by a high incidence rate and mortality. It leads to various cardiac pathophysiological changes, including ischemia/reperfusion injury, inflammation, fibrosis, and ventricular remodeling, which ultimately result in heart failure and pose a significant threat to global health. Although clinical reperfusion therapies and conventional pharmacological interventions improve emergency survival rates and short-term prognoses, they are still limited in providing long-lasting improvements in cardiac function or reversing pathological progression. Recently, cardiac patches have gained considerable attention as a promising therapy for myocardial infarction. These patches consist of scaffolds or loaded therapeutic agents that provide mechanical reinforcement, synchronous electrical conduction, and localized delivery within the infarct zone to promote cardiac restoration. This review elucidates the pathophysiological progression from myocardial infarction to heart failure, highlighting therapeutic targets and various cardiac patches. The review considers the primary scaffold materials, including synthetic, natural, and conductive materials, and the prevalent fabrication techniques and optimal properties of the patch, as well as advanced delivery strategies. Last, the current limitations and prospects of cardiac patch research are considered, with the goal of shedding light on innovative products poised for clinical application.
2076. Response by Jeong et al to Letter Regarding Article, "Early Left Ventricular Unloading or Conventional Approach After Venoarterial Extracorporeal Membrane Oxygenation: The EARLY-UNLOAD Randomized Clinical Trial".2079. Letter by Jha Regarding Article, "Early Left Ventricular Unloading or Conventional Approach After Venoarterial Extracorporeal Membrane Oxygenation: The EARLY-UNLOAD Randomized Clinical Trial".2080. Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction.
作者: Jwan A Naser.;Atsushi Tada.;Tomonari Harada.;Yogesh N V Reddy.;Rickey E Carter.;Jeffrey M Testani.;Michael D Jensen.;Barry A Borlaug.
来源: Circulation. 2024年149卷25期2026-2028页 |